ORKAOruka Therapeutics, Inc.
- GlobeNewswire
Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
EVERLAST-A Week 28 data expected at the end of 3Q 2026; 52-week data for all participants expected in December 2026EVERLAST-B fully enrolled ahead of schedule, with Week 16 data now expected in 4Q 2026Phase 3 program ...
- Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics with a Buy and maintains $120 price target. ...
- Analyst Upgrades
BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target
BTIG analyst Julian Harrison reiterates Oruka Therapeutics with a Buy and maintains $151 price target. ...
- Analyst Upgrades
UBS Maintains Buy on Oruka Therapeutics, Raises Price Target to $130
UBS analyst Michael Yee maintains Oruka Therapeutics with a Buy and raises the price target from $100 to $130. ...
- Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics with a Buy and maintains $120 price target. ...
- GlobeNewswire
Phase 2 Data could Transform these Biotechs from Clinical Promise to Market Validation
DENVER, May 28, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Biotechnology has always been a sector driven by inflection points, and few milestones matter more than Phase 2 clinical data. For emerging biotech ...
- GlobeNewswire
Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
MENLO PARK, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment ...
- Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics with a Buy and maintains $120 price target. ...
- Analyst Upgrades
BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target
BTIG analyst Julian Harrison reiterates Oruka Therapeutics with a Buy and maintains $151 price target. ...
- GlobeNewswire
Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
ORKA-001 EVERLAST-A 16-week data showed 63.5% PASI 100 rate and a favorable tolerability profile, with longer-term data expected in 2H 2026 ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated with data expected ...
- GlobeNewswire
Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma
SEATTLE and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve and the Company) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global ...
- PR Newswire
Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology
Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") and Oruka Therapeutics, Inc. (Nasdaq: ORKA) ("Oruka") today announced that Halozyme's... ...
- Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Oruka Therapeutics, Raises Price Target to $120
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Oruka Therapeutics with a Buy and raises the price target from $75 to $120. ...
- GlobeNewswire
Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering
MENLO PARK, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (NASDAQ:ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and ...
- Analyst Upgrades
UBS Maintains Buy on Oruka Therapeutics, Raises Price Target to $100
UBS analyst Michael Yee maintains Oruka Therapeutics with a Buy and raises the price target from $75 to $100. ...
- Analyst Upgrades
Barclays Maintains Overweight on Oruka Therapeutics, Raises Price Target to $160
Barclays analyst Etzer Darout maintains Oruka Therapeutics with a Overweight and raises the price target from $78 to $160. ...
- GlobeNewswire
Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering
MENLO PARK, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (NASDAQ:ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and ...
- Analyst Upgrades
BTIG Maintains Buy on Oruka Therapeutics, Raises Price Target to $151
BTIG analyst Julian Harrison maintains Oruka Therapeutics with a Buy and raises the price target from $78 to $151. ...
- GlobeNewswire
Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis
ORKA-001 achieved 63.5% (40/63) PASI 100 at Week 16 Favorable safety profile consistent with the IL-23p19 class Updated Phase 1 PK/PD data continue to support the potential for once-yearly dosing, with longer-term ...
- GlobeNewswire
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026
MENLO PARK, Calif., April 26, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the ...
- Analyst Upgrades
Wedbush Maintains Outperform on Oruka Therapeutics, Raises Price Target to $85
Wedbush analyst Martin Fan maintains Oruka Therapeutics with a Outperform and raises the price target from $45 to $85. ...
- Analyst Upgrades
Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $125 Price Target
Guggenheim analyst Yatin Suneja reiterates Oruka Therapeutics with a Buy and maintains $125 price target. ...
- Analyst Upgrades
BTIG Maintains Buy on Oruka Therapeutics, Raises Price Target to $78
BTIG analyst Julian Harrison maintains Oruka Therapeutics with a Buy and raises the price target from $73 to $78. ...
- Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Oruka Therapeutics, Raises Price Target to $70
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Oruka Therapeutics with a Buy and raises the price target from $40 to $70. ...
- Analyst Upgrades
Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $125 Price Target
Guggenheim analyst Yatin Suneja reiterates Oruka Therapeutics with a Buy and maintains $125 price target. ...